BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32293329)

  • 1. Clinical characteristics and risk factors of 47 cases with ruptured neuroblastoma in children.
    Qin H; Yang S; Cai S; Ren Q; Han W; Yang W; Cheng H; Ma X; Wang H
    BMC Cancer; 2020 Mar; 20(1):243. PubMed ID: 32293329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
    Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
    Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor rupture in hepatoblastoma: A high risk factor?
    Pondrom M; Pariente D; Mallon B; Taque S; Branchereau S; Chardot C; Laithier V; Tabone MD; Lejeune J; Faure-Conter C; Saumet L; Vérité C; Aerts I; Brugières L; Fresneau B
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28549. PubMed ID: 32618436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Berlanga P; Pasqualini C; Pötschger U; Sangüesa C; Castellani MR; Cañete A; Luksch R; Elliot M; Schreier G; Kropf M; Morgenstern D; Papadakis V; Ash S; Ruud E; Brock P; Wieczorek A; Kogner P; Trahair T; Ambros P; Boterberg T; Castel V; Valteau-Couanet D; Ladenstein R
    Eur J Cancer; 2021 Feb; 144():1-8. PubMed ID: 33316634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [N-myc gene copies in children with neuroblastoma and its clinical significance].
    Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
    Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
    Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
    Ehlert K; Hansjuergens I; Zinke A; Otto S; Siebert N; Henze G; Lode H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
    Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical risk factors for patients with ruptured hepatoblastoma in children: a retrospective study from a single center in China.
    Chang S; Yang S; Yang W; Qin H; Cheng H; Chang X; Zhu Z; Yin J; Ren Q; Yu S; Wang H
    Pediatr Surg Int; 2023 Jan; 39(1):76. PubMed ID: 36622431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
    Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
    Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.
    Rubie H; Coze C; Plantaz D; Munzer C; Defachelles AS; Bergeron C; Thomas C; Chastagner P; Valteau-Couanet D; Michon J; Mosseri V; Hartmann O;
    Br J Cancer; 2003 Nov; 89(9):1605-9. PubMed ID: 14583756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
    Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
    Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.
    Du J; Yuan X
    Eur J Pediatr; 2024 Jan; 183(1):185-202. PubMed ID: 37855927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
    Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
    J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroblastoma in adolescents: the Italian experience.
    Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
    Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.